Source link : https://www.newshealth.biz/health-news/no-benefit-to-adding-chemotherapy-in-older-adults-with-nsclc/
TOPLINE: Immunotherapy plus chemotherapy — the standard treatment for non–small cell lung cancer (NSCLC) — does not confer survival benefits over immunotherapy alone but does increase the side-effect burden in older patients. METHODOLOGY: Clinical trials have shown that combining immunotherapy and chemotherapy leads to longer overall survival in patients with NSCLC, but these trials often […]
Author : News Health
Publish date : 2024-03-14 03:54:10
Copyright for syndicated content belongs to the linked Source.
in Health